DocDollars

Otsuka Pharmaceutical Development & Commercialization, Inc.

NJ · United States · Reporting entity ID 100000010725

Total reported 2019–2025
$226.5M
#54 of 2,960 reporting companies — 0.3% of all reported industry payments
$24.9M in general payments across 22,701 records, plus $201.6M in research funding across 6,669 records.

How it breaks down

General payments $24,913,616
Research funding $201,627,720

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Otsuka Pharmaceutical Development & Commercialization, Inc. reported $226.5M to US doctors and teaching hospitals from 2019 to 2025, ranking #54 of 2,960 reporting companies. 89% of that was research funding and 11% general payments such as consulting, speaking, food and travel. 22,701 general payment records and 6,669 research records were filed.

Common questions about Otsuka Pharmaceutical Development & Commercialization, Inc.

How much has Otsuka Pharmaceutical Development & Commercialization, Inc. paid US doctors?

Otsuka Pharmaceutical Development & Commercialization, Inc. reported $226,541,336 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $24,913,616 in general payments, $201,627,720 in research funding.

How does Otsuka Pharmaceutical Development & Commercialization, Inc. rank among drug and device companies?

It ranks #54 of 2,960 reporting entities by total reported value, about 0.3% of all industry payments in the dataset.

Does a payment from Otsuka Pharmaceutical Development & Commercialization, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.